SEC Tracker
Get the app

Cyclerion Therapeutics KRSA

Cyclerion Therapeutics Q2 FY24: revenue $0; diluted EPS −$0.53

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract

Key figures from this report

These are the numbers Cyclerion Therapeutics reported for Q2 FY24, the quarter ended Jun 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$0No year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$1.3MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.53No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$4.6MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations−$1.1MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Cyclerion Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. America Great Health AAGH
  2. AbbVie ABBV public float $325.1B, Jun 30, 2025
  3. Abeona Therapeutics ABEO public float $273M, Jun 30, 2025
  4. Abbott Laboratories ABT public float $232.2B, Jun 30, 2025
  5. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.